Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NSC 631570

Drug Profile

NSC 631570

Alternative Names: NSC B238865; Ukrain; UKSR 222; W122

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nowicky Pharma
  • Developer Military Medical Academy; Nowicky Pharma; Ukrainian Anti-Cancer Institute
  • Class Antineoplastics; Berberine alkaloids; Phenanthridines
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer

Highest Development Phases

  • Marketed Cancer
  • No development reported Influenza virus infections; Pancreatic cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer(Combination therapy, Late-stage disease) in Germany (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer(Combination therapy, Late-stage disease) in Ukraine (IV, Infusion)
  • 10 Oct 2002 A study has been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top